Long-awaited restoration in the tax treatment of employee share schemes (ESS) and the announcement that Australian manufacturers of medical devices will be able to register routine medical devices using certification from European bodies were amid the changes that AusBiotech warmly welcomed when the government released its Industry Innovation and Competitiveness Agenda (IICA). [ + ]

Australia excels in biomedical research but sucks at commercialisation. Professor Frank Gannon says that needs to change. [ + ]

CSL (ASX:CSL) chairman Professor John Shine used his AGM address to announce a $950m share buyback and detail the company's achievements over the past 12 months. [ + ]

Recognised as this year's distinguished Lemberg Medalist at the ComBio2014 meeting, Professor Marilyn Anderson reflects on a research career that began with organic chemistry and moved through oncogenes and cloning technology to settle in plant biology, and continues to span basic research to commercialisation. [ + ]

The current Ebola crisis has demonstrated that 'inadvertent' contamination is very hard to eradicate and can have deadly consequences. [ + ]

While there is absolutely no scientific evidence that crystals can be used to predict the future or provide protection or healing, they play a critical role in establishing the structure of matter.

For the first time, researchers have been able to open a kind of window into the inner workings of a lithium-ion battery. Using a neutron beam, the researchers were able to track the flow of lithium atoms into and out of an electrode in real time as a battery charged and discharged.

All five HCV genotype 3 patients completing treatment during a pilot trial of BIT225 with IFN/RBV had undetectable virus levels 12 weeks post-treatment. [ + ]

When it comes to finding new sources of energy, the Australian Plasma Fusion Research Facility (APFRF) is looking onwards and upwards - quite literally, in fact.

The sciences are producing huge amounts of data and it is humanly impossible to keep up with this ever-growing body of scientific material. How can researchers deal with this volume of information?

Regeneus (ASX:RGS) has given its side of the story over a 7:30 report airing concerns regarding the company's Hi-Q-Cell stem cell therapy and its use by injured AFL players. [ + ]

With the potential to transform medical research, the Medical Research Future Fund needs the science community to get behind it. [ + ]

Phosphagenics' TPM-Tretinoin drug candidate outperformed the market leader during a phase II trial, with the results suggesting that TPM itself has inherent anti-acne qualities. [ + ]

Prima BioMed (ASX:PRR) has proposed to buy immuno-oncology company Immutep, in what chair Lucy Turnbull considers to be the most significant move in the company's history. [ + ]

A new technique for monitoring BK viral loads in kidney transplant patients offers the potential to improve patient outcomes and reduce clinical load. [ + ]